Adrenoleukodystrophy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Adrenoleukodystrophy

Adrenoleukodystrophy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Adrenoleukodystrophy (ALD) is a rare genetic condition that causes the buildup of very long chain fatty acids (VLCFAs) in the brain. When VLCFAs accumulate, they destroy the protective myelin sheath around nerve cells, responsible for brain function. Mutations in the ABCD1 gene cause X-linked adrenoleukodystrophy. The ABCD1 gene provides instructions for producing the adrenoleukodystrophy protein (ALDP), which is involved in transporting certain fat molecules called very long-chain fatty acids (VLCFAs) into peroxisomes. ABCD1 gene mutations result in a shortage (deficiency) of ALDP.

Epidemiology- The prevalence of ALD is estimated to be between 1 in 10,000 and 1 in 17,000 individuals in the general population.

Competitive landscape of Adrenoleukodystrophy includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Adrenoleukodystrophy across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Adrenoleukodystrophy Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Adrenoleukodystrophy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

S. No     Asset     Company             Stage

1            Lenti-D bluebird bio       Phase 3

2            MIN-102             Minoryx Therapeutics, S.L.          Phase 3

3            MD1003             MedDay Pharmaceuticals SA      Phase 3

4            Cholic Acids       Travere Therapeutics, Inc.           Phase 3

5            MGTA-456         Magenta Therapeutics, Inc.         Phase 2